Product image of Ipinzan (Metformin Hydrochloride, Vildagliptin) supplied by GNH India

Ipinzan

Active Ingredient:
Metformin Hydrochloride, Vildagliptin
Origin:
EU

Ipinzan (Metformin Hydrochloride, Vildagliptin)

Metformin Hydrochloride and Vildagliptin, the active ingredients in Ipinzan, are a biguanide and a DPP‑4 inhibitor presented as oral tablets for oral use. They are indicated for the treatment of type 2 diabetes mellitus in adult patients when diet, exercise, and monotherapy are insufficient. The combination improves glycemic control by reducing hepatic glucose output and enhancing insulin secretion in a glucose‑dependent manner.

GNH India supplies Ipinzan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring consistent quality and regulatory compliance across markets.

Manufacturer / TM Owner

Zentiva, K.S.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Ipinzan, a fixed‑dose combination of metformin and vildagliptin, is employed in the management of type 2 diabetes mellitus.

  • Type 2 diabetes mellitus: lowers fasting plasma glucose and improves overall glycemic control.
  • Type 2 diabetes mellitus (post‑prandial): reduces post‑prandial glucose excursions.
  • Type 2 diabetes mellitus (HbA1c): helps achieve target HbA1c levels when added to diet and exercise.

How It Works

  • Metformin acts primarily by inhibiting hepatic gluconeogenesis and increasing peripheral insulin sensitivity, thereby decreasing glucose production. Vildagliptin selectively blocks the enzyme dipeptidyl peptidase‑4 (DPP‑4), which prolongs the activity of endogenous incretin hormones such as GLP‑1 and GIP, leading to glucose‑dependent enhancement of insulin secretion and suppression of glucagon release. The combined actions result in improved glycemic control through complementary mechanisms.

Side Effects

The most frequently reported adverse reactions with Ipinzan involve the gastrointestinal system, while rare but serious events may also occur.

Common Side Effects

  • Nausea: mild to moderate feeling of sickness.
  • Diarrhea: loose stools occurring intermittently.
  • Abdominal discomfort: cramping or pain in the stomach area.
  • Headache: mild to moderate head pain.
  • Metallic taste: transient alteration in taste perception.
  • Vomiting: occasional episodes of expulsion of stomach contents.

Serious or Rare Side Effects

  • Lactic acidosis: rare but potentially fatal accumulation of lactate.
  • Severe hypoglycemia: especially when combined with insulin or sulfonylureas.
  • Pancreatitis: inflammation of the pancreas presenting with abdominal pain.
  • Stevens‑Johnson syndrome: severe skin reaction with blistering.
  • Hepatic dysfunction: abnormal liver enzyme elevations.
  • Anaphylactic reaction: acute allergic response requiring immediate care.

Precautions & Warnings

When prescribing Ipinzan, clinicians should consider several precautionary measures to ensure patient safety.

  • Renal function assessment: evaluate eGFR before initiating and periodically thereafter.
  • Hepatic disease monitoring: use with caution in patients with liver impairment.
  • Hypoglycemia risk: monitor blood glucose when combined with insulin or sulfonylureas.
  • Pregnancy and lactation: avoid unless benefits outweigh potential risks.
  • Alcohol consumption: limit intake to reduce risk of lactic acidosis.
  • Store at ambient temperature: keep in original packaging, protect from moisture and light.

Avoid Interactions

Ipinzan may interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid)

  • Insulin or sulfonylureas: increased risk of hypoglycemia.
  • Iodinated contrast media: may precipitate metformin‑associated lactic acidosis in renal impairment.
  • Cimetidine: can raise metformin plasma concentrations.

Moderate Interactions (Monitor Closely)

  • Beta‑blockers: may blunt hypoglycemia warning signs.
  • Diuretics (thiazides): can affect renal clearance of metformin.

Frequently Asked Questions

Ipinzan is a prescription oral medication that combines metformin hydrochloride and vildagliptin. It is indicated for the treatment of type 2 diabetes mellitus in adults, helping to lower blood glucose levels when diet, exercise, and single‑agent therapy are insufficient.

Metformin reduces hepatic glucose production and improves peripheral insulin sensitivity, while vildagliptin inhibits the enzyme DPP‑4, prolonging the action of incretin hormones that increase insulin release and suppress glucagon in a glucose‑dependent manner. Together they provide complementary glucose‑lowering effects.

The dose of Ipinzan is individualized by the prescribing healthcare professional based on the patient’s clinical condition, renal function, and response to therapy. Specific dosing regimens are not provided here and should be obtained from the prescriber’s instructions.

Safety data for Ipinzan in pregnancy and lactation are limited. Generally, the combination is avoided unless the potential benefit justifies the potential risk to the fetus or infant. Clinicians should discuss alternative treatment options with pregnant or nursing patients.

To request Ipinzan, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Ipinzan combines a biguanide (metformin) with a DPP‑4 inhibitor (vildagliptin), offering dual mechanisms of action. Compared with metformin alone, it provides greater post‑prandial glucose control, and unlike sulfonylureas, it has a lower intrinsic risk of hypoglycemia when used as monotherapy.

Ipinzan tablets should be stored at ambient temperature, below 25 °C, in the original container to protect them from moisture and light. Keep the product out of reach of children and do not use after the expiry date printed on the packaging.

Ipinzan is taken orally, usually with meals, using a full glass of water. The tablets should be swallowed whole and not split, crushed, or chewed unless specifically instructed by a healthcare professional.

The most serious adverse events include lactic acidosis, severe hypoglycemia (especially when combined with insulin or sulfonylureas), pancreatitis, and rare severe skin reactions such as Stevens‑Johnson syndrome. Patients should be educated to seek immediate medical attention if they experience symptoms suggestive of these conditions.

Ipinzan is contraindicated in patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²), known hypersensitivity to metformin, vildagliptin, or any excipients, and in those with a history of lactic acidosis. Caution is also advised for individuals with significant hepatic disease.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Metformin Hydrochloride, Vildagliptin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT